Hormone Replacement Therapy (HRT) in India and UAE | Complete Patient Guide

• ELIGIBLE CANDIDATES:

• Peri-menopausal or post-menopausal women (natural or surgical) with moderate-to-severe vasomotor symptoms (≥7 hot flushes/day or significant night sweats) significantly impairing quality of life

• Women with confirmed premature ovarian insufficiency (POI) aged under 40, where HRT is strongly recommended until the age of natural menopause (51 years)

• Women with DXA-confirmed osteopenia (T-score −1.0 to −2.5) or osteoporosis (T-score ≤ −2.5) for whom antiresorptive therapy alone is insufficient or not tolerated

• Women experiencing symptomatic genitourinary syndrome of menopause (vaginal dryness, dyspareunia, recurrent UTIs) unresponsive to non-hormonal lubricants

• Women with surgical menopause secondary to bilateral oophorectomy, regardless of age at surgery

• Transgender men on testosterone therapy who require oestrogen supplementation for bone protection

• REQUIRED DIAGNOSTICS BEFORE INITIATION:

• Serum FSH, LH, 17β-estradiol, total and free testosterone, SHBG, AMH (if peri-menopausal)

• Full lipid panel, fasting glucose/HbA1c, liver function tests, renal function

• Thyroid function panel (TSH, Free T4) to exclude hypothyroidism as a mimicker

• Mammography (within 12 months) and clinical breast examination

• Pap smear / cervical cytology (within recommended screening interval)

• Pelvic ultrasound (endometrial thickness baseline; transvaginal preferred)

• DXA bone mineral density scan (lumbar spine L1–L4 and femoral neck)

• Blood pressure measurement and BMI; thrombophilia screen (Factor V Leiden, prothrombin gene mutation, antiphospholipid antibodies) if personal or family history of VTE

• ABSOLUTE CONTRAINDICATIONS:

• Personal history of estrogen-receptor-positive (ER+) breast cancer or endometrial cancer (Stage II+)

• Active or recent (within 12 months) venous thromboembolism (DVT or pulmonary embolism) not on anticoagulation

• Untreated endometrial hyperplasia with atypia

• Active liver disease with elevated transaminases >3× ULN

• Unexplained vaginal bleeding under investigation

• Recent acute arterial thromboembolic event (myocardial infarction, stroke) within 6 months

• Known hereditary thrombophilia (e.g., Protein C/S deficiency, antithrombin III deficiency) — systemic oral HRT; transdermal route may be considered individually

• RELATIVE CONTRAINDICATIONS (individualised risk-benefit discussion required):

• Well-controlled hypertension (transdermal preferred over oral)

• Gallbladder disease (transdermal preferred)

• Migraine with aura (transdermal, low-dose preferred)

• Strong family history of ER+ breast cancer (BRCA1/2 carrier status should be confirmed)

HRT is not a single drug but a spectrum of individualised regimens selected according to menopausal status, uterine status, symptom profile, route preference, and risk stratification.

1. SYSTEMIC ORAL HRT

• Estrogen-only therapy: Conjugated equine estrogens (CEE) 0.3–0.625 mg/day or 17β-estradiol 1–2 mg/day (for hysterectomised women).

• Combined continuous combined (CCC): Daily 17β-estradiol + micronised progesterone 100–200 mg — preferred for post-menopausal women (>12 months amenorrhoea) seeking amenorrhoea.

• Sequential (cyclical) therapy: Estradiol daily + progestogen for 10–14 days per cycle — preferred for peri-menopausal women to maintain predictable withdrawal bleeds.

• Tibolone 2.5 mg/day: Synthetic steroid with mixed estrogenic, progestogenic, and androgenic activity; suited for post-menopausal women with concomitant libido concerns. Not recommended within 5 years of breast cancer diagnosis.

• Key limitation of oral route: First-pass hepatic metabolism elevates SHBG, triglycerides, and clotting factors (renin substrate), modestly increasing VTE risk compared to non-oral routes.

2. TRANSDERMAL DELIVERY SYSTEMS (PREFERRED ROUTE FOR MOST PATIENTS)

• Matrix patches (e.g., Estradot, Climara): Deliver 25–100 µg/day 17β-estradiol through skin twice weekly or weekly; bypasses hepatic first-pass — neutral effect on coagulation and triglycerides, lower VTE risk vs. oral.

• Estradiol gel (Oestrogel, Sandrena): 0.5–1.5 mg/day applied to inner arm or thigh; highly titratable.

• Estradiol spray (Lenzetto): Metered-dose transdermal spray; 1–3 actuations/day.

• Transdermal progestogen: Progesterone gel (Crinone) or Norethisterone-acetate patches (Estalis) used in combination.

3. SUBCUTANEOUS PELLET IMPLANTS (BIOIDENTICAL HORMONE PELLET THERAPY)

• Compounded crystalline 17β-estradiol pellets (25–75 mg) and/or testosterone pellets (12.5–75 mg) inserted subcutaneously into the upper outer buttock or lower abdominal wall via a 4–5 mm incision under local anaesthesia (lidocaine 1%).

• Procedure time: 10–15 minutes; no sutures required (Steri-Strips only).

• Duration of action: 3–6 months; delivers stable, non-pulsatile serum levels without daily administration burden.

• Particularly suited for: Women with malabsorption syndromes, poor patch adherence, or seeking testosterone supplementation for libido, fatigue, and cognitive function.

• Monitoring: Serum estradiol and testosterone levels checked at 4–6 weeks post-insertion to confirm therapeutic range (estradiol 40–120 pg/mL; testosterone 70–150 ng/dL for women).

4. INTRAUTERINE PROGESTERONE DELIVERY

• Levonorgestrel-releasing intrauterine system (LNG-IUS; Mirena 52 mg): Delivers 20 µg/day LNG locally to the endometrium, providing progestogen endometrial protection while systemic estrogen is administered via any route. Reduces systemic progestogen side-effects (bloating, mood changes). Approved for HRT combination use in multiple international guidelines (BMS, ESHRE).

5. VAGINAL / LOCAL ESTROGEN (GENITOURINARY SYNDROME OF MENOPAUSE)

• Ultra-low-dose vaginal estradiol tablets (Vagifem 10 µg), vaginal ring (Estring 7.5 µg/day), or estradiol cream: Minimal systemic absorption; does not require concomitant progestogen in most cases; safe even in most women with a history of breast cancer (per NAMS 2022 position statement).

• Ospemifene 60 mg/day (oral SERM): For women unwilling to use vaginal preparations; effective for dyspareunia.

• Prasterone (intravaginal DHEA 6.5 mg/day): Locally converted to estradiol and testosterone; FDA-approved for dyspareunia.

6. TESTOSTERONE SUPPLEMENTATION FOR WOMEN

• Indicated for hypoactive sexual desire disorder (HSDD) unresponsive to estrogen optimisation.

• Delivered via compounded transdermal cream (1% testosterone) or off-label use of male transdermal gels at female doses (1/10th of male dose).

• Monitoring: Total testosterone, free testosterone, SHBG, haematocrit every 3–6 months.

7. NON-HORMONAL ADJUNCTS (for women with contraindications to HRT)

• SSRIs/SNRIs: Paroxetine 7.5 mg (FDA-approved), Venlafaxine 75 mg for vasomotor symptoms.

• Fezolinetant (Veoza): First-in-class neurokinin 3 receptor antagonist (NK3R); FDA-approved May 2023; reduces hot flush frequency by ~60% without systemic hormonal activity — critical option for ER+ breast cancer survivors.

• Gabapentin 300 mg nocte: Off-label; useful for night sweats and sleep disruption.

• Clonidine 50–150 µg/day: Modest efficacy for vasomotor symptoms in women with cardiovascular comorbidity.

PHASE 1 — PRE-TREATMENT EVALUATION (Days 1–7, typically remote + on-site Day 1)

• Day 1 (Tele-consultation with GAF Healthcare): Upload existing medical records, current medications list, previous hormone test results. GAF's partner gynaecologist or reproductive endocrinologist reviews history and pre-authorises a standardised pre-HRT investigation panel.

• Day 1–3 (On-site Investigations): Arrive at the hospital; complete fasting bloodwork (hormone panel, lipids, glucose, LFTs, TFTs, thrombophilia screen if indicated), mammography, pelvic transvaginal ultrasound, DXA scan, BP and BMI assessment. Pap smear performed if overdue.

• Day 4–5 (Results Review and Regimen Design): Gynaecologist reviews all results and applies validated risk-stratification tools. Breast cancer risk: Tyrer-Cuzick 10-year model. VTE risk: personal/family history + thrombophilia screen. Bone fracture risk: FRAX score. Cardiovascular risk: Framingham 10-year score. A written, individualised HRT prescription with route, formulation, dose, and monitoring schedule is issued.

PHASE 2 — HRT INITIATION (Day 5–7)

• ORAL / TRANSDERMAL / VAGINAL REGIMEN: No hospital admission required. Patient is educated (ideally with a written patient information leaflet) on correct application of patches, gel, or spray; importance of progestogen compliance; symptoms of VTE (leg swelling, chest pain, SOB) requiring emergency presentation; and expected timeline of symptom relief (vasomotor symptoms: 2–4 weeks; urogenital symptoms: 6–12 weeks; bone density improvement: 12–24 months).

• SUBCUTANEOUS PELLET INSERTION (if selected): Performed as an outpatient procedure on Day 5–6. Skin is cleansed, local anaesthetic infiltrated, a trocar is inserted through a 4–5 mm incision in the upper outer buttock, pellet(s) deposited, and wound closed with Steri-Strips. Patient ambulates immediately. No sutures. Mild local bruising/tenderness for 3–5 days. Strenuous lower-body exercise avoided for 72 hours.

PHASE 3 — SHORT-TERM RECOVERY AND TRAVEL CLEARANCE (Days 7–14)

• For transdermal/oral/vaginal HRT: Fit-to-fly within 24–72 hours of prescription. No procedural recovery required. Patient carries a 3-month supply of medication and written prescription (translated if required) for customs clearance.

• For pellet insertion: Rest for 48 hours; avoid swimming and submersion bathing for 5 days. Fit-to-fly typically at Day 5–7 post-procedure. Patient receives a detailed procedural record and insertion site photographs for the next treating physician.

• Follow-up tele-consultation with GAF Healthcare's partner physician at 4–6 weeks post-initiation to review first symptom response, check for side-effects (breakthrough bleeding, breast tenderness, mood changes), and adjust dose if required.

PHASE 4 — LONG-TERM MANAGEMENT (Months 1–12+)

• Serum estradiol (and testosterone if supplemented) re-checked at 4–6 weeks.

• Endometrial thickness ultrasound at 6 months for women on combined HRT with unexpected bleeding.

• Annual mammography, blood pressure review, lipid panel, fasting glucose.

• DXA scan at 2 years to assess bone density response.

• Annual HRT review: assess continued benefit vs. risk; consider duration of use (guidelines support ongoing use as long as quality-of-life benefit outweighs risk, reviewed annually).

• Milestone symptom relief timeline: Vasomotor symptoms (hot flushes/night sweats): 50–75% reduction at 4 weeks, maximal at 12 weeks. Sleep and mood: 4–8 weeks. Urogenital symptoms: 6–12 weeks. Bone density stabilisation: 12 months; improvement at 24 months.